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Cell Permeant Peptide Analogues of the Small Heat
Shock Protein, HSP20, Reduce TGF-b1-Induced CTGF
Expression in Keloid Fibroblasts
Luciana B. Lopes1, Elizabeth J. Furnish1, Padmini Komalavilas1,2, Charles R. Flynn1, Patricia Ashby3,
Adam Hansen1, Daphne P. Ly4, George P. Yang4,5, Michael T. Longaker4, Alyssa Panitch6 and
Colleen M. Brophy1,2
A growing body of evidence suggests the involvement of connective tissue growth factor (CTGF) in the
development and maintenance of fibrosis and excessive scarring. As the expression of this protein requires an
intact actin cytoskeleton, disruption of the cytoskeleton represents an attractive strategy to decrease CTGF
expression and, consequently, excessive scarring. The small heat-shock-related protein (HSP20), when
phosphorylated by cyclic nucleotide signaling cascades, displaces phospho-cofilin from the 14-3-3 scaffolding
protein leading to activation of cofilin as an actin-depolymerizing protein. In the present study, we evaluated
the effect of AZX100, a phosphopeptide analogue of HSP20, on transforming growth factor-b-1 (TGF-b1)-induced
CTGF and collagen expression in human keloid fibroblasts. We also examined the effect of AZX100 on scar
formation in vivo in dermal wounds in a Siberian hamster model. AZX100 decreased the expression of CTGF and
type I collagen induced by TGF-b1, endothelin, and lysophosphatidic acid. Treatment with AZX100 decreased
stress fiber formation and altered the morphology of human dermal keloid fibroblasts. In vivo, AZX100
significantly improved collagen organization in a Siberian hamster scarring model. Taken together, these results
suggest the potential use of AZX100 as a strategy to prevent excessive scarring and fibrotic disorders.
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INTRODUCTION
Transforming growth factor-b (TGF-b) is a multifunctional
protein that regulates cell growth, differentiation, motility,
and extracellular matrix production in the normal wound-
healing process, but has also been implicated in excessive
scar formation and fibrotic disorders (Yang et al., 2003; Leask
and Abraham, 2004; Lu et al., 2005; Phan et al., 2005). TGF-
b1 (and possibly TGF-b2) seems to be important for optimal
wound healing in the first week after wounding, although
persistent expression later in wound healing suggests it may
be critical in the formation of hypertrophic scars (Lu et al.,
2005; Kryger et al., 2007).
In fibroblasts, TGF-b1 stimulates the expression of
connective tissue growth factor (CTGF). CTGF has been
proposed to mediate some of the profibrotic effects of TGF-b,
including fibroblast proliferation and the production of
extracellular matrix proteins such as collagen and fibronectin
(Duncan et al., 1999; Leask and Abraham, 2004, 2006).
Elevated levels of CTGF were found in dermal fibrotic lesions
such as scleroderma (Abraham et al., 2000) and keloids
(Igarashi et al., 1996; Khoo et al., 2006), as well as in fibrotic
lesions of other organs (Ito et al., 1998; Paradis et al., 1999).
To further support the role of CTGF in fibrosis, it has been
demonstrated that simultaneous co-injection of CTGF and
TGF-b caused sustained fibrotic response in vivo, whereas
injection of TGF-b alone caused only a transient response
(Mori et al., 1999).
A growing body of evidence implicates cytoskeletal
reorganization in the modulation of CTGF expression
(Muehlich et al., 2007). Whereas stabilization of the actin
cytoskeleton increases CTGF expression, actin depolymer-
ization or increased monomeric actin decreases the expres-
sion of CTGF (Ott et al., 2003; Muehlich et al., 2007). In
addition, increased levels of cAMP have been shown to
abolish TGF-b-induced reorganization of the actin cytoske-
leton as well as TGF-b-induced CTGF expression (Kothapalli
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et al., 1998; Santibanez et al., 2003). We have demonstrated
that phosphorylation of the small heat-shock-related protein,
heat shock protein 20 (HSP20), on serine 16, is one of the
downstream events in the cAMP signaling pathway (Beall
et al., 1999; Woodrum et al., 2003). A phosphorylated
peptide analogue of the region surrounding the phosphoryla-
tion site of HSP20 (WLRRAS*APLPGLK) in which the serine is
phosphorylated (S*), when attached to a protein transduction
domain (PTD; to allow penetration into the cell) mimics the
effects of activation of cyclic nucleotide signaling pathways
(Komalavilas et al., 2008). This peptide, referred to as
AZX100, relaxes smooth muscles from a variety of different
species (Flynn et al., 2003; McLemore et al., 2004) and
inhibits smooth muscle migration (Tessier et al., 2004).
AZX100 also prevents a form of vascular scarring, intimal
hyperplasia, in an organ culture model of human saphenous
vein (Tessier et al., 2004). In addition, treatment of cultured
cells with this peptide leads to changes in cellular morpho-
logy (loss of actin stress fibers and increases in monomeric
g-actin) similar to the changes observed with activation of the
cAMP signaling pathway (Dreiza et al., 2005; Komalavilas
et al., 2008).
At least one of the mechanisms by which AZX100 exerts
these cellular effects has been recently identified. Phospho-
peptide analogues of HSP20, but not scrambled or nonpho-
sphorylated control peptides bind to the intracellular
scaffolding protein, 14-3-3 (Dreiza et al., 2005). The binding
of phosphorylated HSP20 competes with the binding of
another protein, phospho-cofilin, to 14-3-3 (Dreiza et al.,
2005). When not bound to 14-3-3, cofilin becomes depho-
sphorylated and activated as an actin-depolymerizing pro-
tein. This leads to disruption of the actin cytoskeleton. The
cytoskeleton represents, therefore, a promising therapeutic
target to reduce the expression of CTGF and excessive scar
formation. Hence, we postulated that AZX100 might ame-
liorate the fibrotic effects of TGF-b1, and possibly other
mediators of fibrosis. To date, there are no therapeutic drugs
available that target the cytoskeleton as a means to prevent
excessive scarring and fibrosis.
RESULTS
AZX100 treatment decreased TGF-b1-induced CTGF and type I
collagen expression
The concentration of TGF-b1 necessary to increase CTGF
expression in keloid fibroblasts after 24 hours was deter-
mined. No significant increase (Po0.05) in the CTGF
expression was observed when cells were stimulated with
0.62 ngml1 TGF-b1. At 1.2 and 2.5 ngml1, TGF-b1
significantly (Po0.05) increased CTGF expression in a
dose-dependent manner (Figure 1a and b).
We next evaluated the effect of AZX100 on the expression
of CTGF and type I collagen in TGF-b1-stimulated cells. At
50 mM, AZX100 decreased the TGF-b1-induced expression of
both CTGF and collagen by 33.6±11.1 and 34.2±18.5%,
respectively (Po0.05) when cells were stimulated with
1.2 ngml1 of TGF-b1 (Figure 1c–e). Lower concentrations
of AZX100 had no effect (data not shown). A comparable
reduction of CTGF and collagen (24±7.4 and 32.4±11.1%,
respectively) was observed with AZX100 (50 mM) treatment at
a higher dose of TGF-b1 (2.5 ngml1; Figure 1c–e). The
experiments were conducted with cells from three different
patients, and consistent results were obtained.
To ensure that the PTD is necessary, but not sufficient for
AZX100 activity, the following control peptides were used:
the HSP20 phosphopeptide (without a PTD) and the PTD
(YARAAARQARA) alone. Neither the HSP20 phosphopeptide
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Figure 1. AZX100 reduces TGF-b1-induced expression of CTGF and collagen
in human keloid fibroblasts. Human keloid fibroblasts were serum-starved in
DMEM medium containing 0.5% fetal bovine serum for 48 hours before
treatment.(a, b) Cells treated with different doses of TGF-b1 for 24 hours.
Representative western blots of CTGF and GAPDH are shown in (a). CTGF
levels were quantified relative to GAPDH expression to correct for loading
differences and normalized to untreated levels. Data are shown in (b), and are
expressed as mean±standard deviation of 3–6 experiments. *Po0.05
compared to the untreated cells. (c–e) TGF-b1-stimulated cells were treated
with either AZX100 (50 mM), the protein transduction domain (PTD), or free
HSP20 phosphopeptide without the PTD. Representative western blots of
CTGF, collagen, and b-actin are shown in (c). CTGF and collagen levels were
quantified relative to GAPDH expression to correct for loading differences
and normalized to untreated (U) levels. Data are shown in (d) and (e) and are
expressed as mean±standard deviation of 4–6 experiments. *Po0.05
compared to the TGF-b1 stimulation indicates no AZX100 treatment.
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nor the transduction domain alone had an effect on TGF-b1-
induced expression of CTGF and collagen expression (Figure
1c–e).
AZX100 decreased the expression of CTGF and collagen
induced by other profibrotic agents
Besides TGF-b, many other substances released at the
wound-healing site have profibrotic activity and stimulate
the expression of CTGF, including lysophosphatidic acid
(LPA), thrombin, and endothelin (ET). Hence, the effect of
AZX100 on CTGF and collagen expression induced by these
additional profibrotic agents was examined. The expression
of CTGF and collagen was 1.7-fold higher after ET (50 nM)
stimulation compared to untreated (control) cells, whereas
LPA (25 mM) stimulation led to a 2.0 and 2.1 times higher
CTGF and collagen expression, respectively. Thrombin, on
the other hand, had no effect on the expression of CTGF or
collagen (Figure 2a–c). AZX100 treatment significantly
inhibited the ET and LPA-induced increases in CTGF and
collagen (Figure 2d–f). Thus, AZX100 inhibits CTGF and
collagen expression induced by multiple profibrotic agonists.
AZX100 reduced stress fiber formation and phosphorylation of
cofilin
As an intact actin cytoskeleton is needed for CTGF expres-
sion, we next examined the effect of AZX100 on stress fiber
formation. Staining of the actin cytoskeleton with Alexa 450
phalloidin revealed that keloid fibroblasts had robust stress
fibers, which were enhanced by TGF-b1 stimulation (Figure
3a, c and e). AZX100 treatment led to decreased stress fiber
staining and altered the morphology of the cells that were
either untreated (Figure 3b) or stimulated with TGF-b1 at
1.2 ngml1 (Figure 3d). The effect of AZX100 was not as
strong on cells stimulated with 2.5 ngml1 of TGF (Figure 3f).
No signs of cell detachment were observed after 3 days,
showing that the effect of the peptide is not associated with
cell death (Figure 3g). Similar decreases in stress fibers have
been observed in response to AZX100 treatment when other
mediators (LPA or serum) are used to stimulate stress fiber
formation in 3T3 fibroblasts (Dreiza et al., 2005).
The effect of AZX100 treatment on the expression of
a-smooth muscle actin (a-SMA), a hallmark of the differentia-
tion of fibroblasts into myofibroblasts (Tomasek et al., 2002),
was also evaluated. Keloid-derived fibroblasts constitutively
expressed a-SMA, which was further increased upon TGF-b1
stimulation (Figure 3h–i). AZX100 treatment inhibited the
TGF-b1-induced expression of a-SMA without affecting the
expression of b-actin (Figure 3h–i). AZX100 also led to
significant decreases in basal a-SMA expression.
Because AZX100-induced disruption of the actin cyto-
skeleton has been correlated with cofilin dephosphorylation
due to the displacement of cofilin from its binding site to the
protein 14-3-3 (Dreiza et al., 2005), the effect of AZX100
treatment on cofilin phosphorylation in TGF-b1-stimulated
keloid fibroblasts was evaluated. We observed that the
phospho-cofilin/cofilin ratio was increased 1.5 and 2.3 times
after stimulation with TGF-b1 at 1.2 and 2.5 ngml1,
respectively. AZX100 treatment decreased this ratio by
27.0±4.1 and 24.4±8.8% in cells stimulated with TGF-b1
at 1.2 and 2.5 ngml1, respectively (Figure 4).
AZX100 did not influence SMAD3 phosphorylation
The classical pathway activated by TGF-b1 implicated in
increased CTGF expression involves the phosphorylation of
SMAD2/3, which forms a complex with SMAD4 that
translocates to the nucleus and binds CTGF promoters at
the Smad consensus sequence, CAGAC (Leask and Abraham,
2004). To evaluate the potential involvement of this pathway
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Figure 2. AZX100 reduces endothelin- and LPA-induced expression of CTGF
and collagen in human keloid fibroblasts. Cells were serum-starved in DMEM
medium containing 0.5% FBS for 48 hours, before treatment. (a–c) Cells were
treated with several doses of endothelin (10–50 nM), lysophosphatidic acid
(LPA, 10–50mM), or thrombin (50–150 nM) for 24 hours. Representative
Western blots of CTGF, collagen, and GAPDH are shown in (a). CTGF and
collagen levels were quantified relative to GAPDH expression to correct for
loading differences and normalized to untreated (U) levels. Data are shown in
(b) and (c) and are expressed as mean±standard deviation of 3–4
experiments. (d–f) Cells were stimulated with endothelin (50 nM) and LPA
(25mM) in the presence or absence of AZX100 (50 mM) for 24 hours.
Representative western blots of CTGF, collagen, and GAPDH are shown in
(d). (e, f) The Western blot bands were quantified by densitometry, and CTGF
and collagen expressions were related to GAPDH expression to correct for
loading differences. The expression of CTGF and collagen in untreated cells
was set to 1 for comparison of different blots. Data expressed as
mean±standard deviation of three experiments. *Po0.05 compared to the
TGF-b1 stimulation.
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in the effect of AZX100, we investigated whether AZX100
treatment had any effect on the phosphorylation of SMAD3.
As expected, TGF-b1 increased SMAD3 phosphorylation
(Figure 5). AZX100 did not alter TGF-b1-induced SMAD3
phosphorylation. This finding suggests that the observed
effect of AZX100 on the cytoskeleton and CTGF is likely
independent of SMAD signaling pathway.
AZX100 improved the collagen organization in an in vivomodel
A Siberian hamster model of scarring was selected because
unlike normal laboratory rodents, this animal responds
to environmental stressors, as evidenced by changes in
behavior, body mass, and cortisol levels, which impact
wound healing (Castro and Matt, 1997; Detillion et al.,
2004). In addition, it has a broad upper back that provides a
surgical site that is inaccessible to chewing and scratching by
the animal. Incisions were treated with a single injection of
either 1mM AZX100 or saline immediately after wound
closure. Samples were harvested at 7, 14, and 21 days,
processed, and stained with Masson’s trichrome. Representa-
tive images for control and treated incisions at all time points
are shown in Figure 6a–f. As in other rodent studies of the
neodermis (Shah et al., 1995), histological slices are shown at
a magnification of 200 times. Masson’s trichrome stain was
selected to reveal collagen fibers and more closely compare
our results with previous published scoring scales (Shah et al.,
1995; Beausang et al., 1998), which are in use in clinical
trials conducted by Renovo (www.renovo.com). Slides were
blindly examined by a pathologist for collagen orientation,
density, and maturity (Figure 6g). For all categories, a score of
zero corresponds to normal skin, thus the lower the score, the
better the appearance of the scar (Beausang et al., 1998).
Collagen fiber orientation was assessed by its similarity to the
normal basket-weave pattern of adjacent control skin;
however, the differences between AZX100 and control
groups were not significant. Collagen fiber density was
assessed by its similarity to the density of adjacent normal
skin, and there is a significant improvement in collagen fiber
density with AZX100 treatment at 21 days (Po0.05).
Collagen fiber maturity was assessed by fiber thickness and
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Figure 3. Effect of TGF-b1 and AZX100 treatment on stress fiber formation
and a-SMA expression. Human keloid fibroblasts were either untreated (a),
treated with AZX100 (50 mM) (b), TGF-b1 at 1.2 ngml1 (c), TGF-b1 at
2.5 ngml1 (d), TGF-b1 (1.2 ngml1)þAZX100 (50 mM) (e), or TGF-b1
(2.5 ngml1)þAZX100 (50 mM) (f) for 24 hours. The cells were fixed and
stained with Alexa 350 phalloidin to visualize the actin cytoskeleton.
Bar¼100 mm. Representative western blots of a-SMA, GAPDH, and b-actin in
untreated cells, cells treated with AZX100 (50mM), with TGF-b1 (2.5 ngml1),
or cells treated with TGF-b1 (2.5 ngml1)þAZX100 (50 mM). (g) Phase
contrast microscopic images of untreated cells and cells treated with AZX100
for 3 days; bar¼ 200 mm. (h) a-SMA levels were quantified relative to GAPDH
expression to correct for loading differences and normalized to untreated
levels. (i) Data are expressed as mean±standard deviation of 4–6
experiments. *Po0.05 AZX100-treated cells compared to untreated and
AZX100þ TGF-b1 compared to the TGF-b1 stimulation alone.
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Figure 4. AZX100 treatment reduces TGF-b1-induced cofilin
phosphorylation. Human keloid fibroblasts were treated as previously
indicated.(a) Representative Western blots of cofilin, phospho-cofilin, and
b-actin. Cofilin and phospho-cofilin levels were quantified relative to b-actin
expression to correct for loading differences and normalized to untreated (U)
levels. Data are shown in (b) and are expressed as mean±standard deviation
of the ratio phosphorylated cofilin/cofilin from 3–4 experiments. *Po0.05
compared to the TGF-b1 stimulation.
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length compared to that of adjacent normal skin, and there is
also a significant improvement in collagen fiber maturity with
AZX100 treatment at 21 days (Po0.05). The individual
collagen scores were also combined into a total collagen
score. At 7 and 14 days, both treated and control scars
appeared similar with comparable collagen composite
scores. However, at 21 days, a significant improvement
emerged in the treated group relative to the control group,
with collagen composite scores of 2.9±0.3 and 4.6±0.5,
respectively.
DISCUSSION
In the present study we investigated the potential use of the
peptide AZX100 for the prevention of excessive scarring and
fibrotic disorders. AZX100 decreased TGF-b1-induced ex-
pression of CTGF and type I collagen in cultured keloid
fibroblasts (Figure 1). As CTGF appears to be involved in
inducing collagen expression (Duncan et al., 1999), the effect
of AZX100 on collagen expression likely results from its
ability to decrease the expression of CTGF. AZX100 did not
alter TGF-b1-induced SMAD signaling (Figure 5), hence the
effects of AZX100 appear to be SMAD independent.
The reduction in CTGF expression caused by AZX100
could be attributed to its effect on the actin cytoskeleton.
AZX100 displaces the actin accessory protein cofilin from its
binding site on the 14-3-3 adapter protein. Such displace-
ment leads to dephosphorylation and activation of cofilin,
which, in turn, mediates actin depolymerization and stress
fiber disruption (Gohla and Bokoch, 2002; Dreiza et al.,
2005). In a previous study (Dreiza et al., 2005), we showed
that cofilin displacement occurs in the presence of 10 and
25 mM of AZX100; in this study, the concentration of AZX100
was higher (50 mM), and thus, enough to prevent the binding
of cofilin to 14-3-3. Cofilin dephosphorylation by AZX100
was confirmed in this study in TGF-b1-stimulated cells
(Figure 4). It seems, therefore that SMAD-independent
cytoskeleton changes may be a major determinant of TGF-
b1-induced CTGF production. Indeed, several studies have
shown that disruption of the cytoskeleton by cytochalasin D
reduces the stimulated expression of CTGF in renal fibro-
blasts and rat mesangial cells (Hahn et al., 2000; Heusinger-
Ribeiro et al., 2001). Recently, Muehlich et al. (2007) have
proposed a molecular mechanism for such a phenomenon.
Using techniques that involve coexpression of mutant actins
and different CTGF promoter constructs, these authors
observed that the CTGF gene promoter contains an actin-
sensitive site, which may be activated by monomeric actin.
Their data indicate an inverse relationship between CTGF
expression and depolymerized actin.
Another important observation of the present study is that
AZX100 reduces the expression of a-SMA (Figure 3). This
protein is a hallmark of the differentiation of fibroblasts into
myofibroblasts, a process that appears to contribute substan-
tially to the development of fibrosis (Desmouliere et al.,
2005). Although the precise mechanism by which AZX100
reduces a-SMA expression in keloid fibroblasts remains to be
determined, it should be mentioned that a-SMA expression
increases with force tension (Wang et al., 2003). Thus, the
ability of AZX100 to reduce a-SMA expression may also be
related to the cytoskeleton-disrupting activity of AZX100.
Besides TGF-b, a multitude of cytokines, growth factors,
and proteins are released at the wound-healing site. Many of
these compounds stimulate profibrotic activity, such as LPA
and ET (Hahn et al., 2000; Shi-Wen et al., 2004). Thus, it is
important for a potential antifibrotic drug to be able to inhibit
the effects of multiple profibrotic mediators. AZX100 was
also able to reduce CTGF expression induced by LPA and ET
(Figure 2). As the signaling pathways used by these molecules
are diverse, the reduction of ET- and LPA-induced CTGF
expression by AZX100 suggests that AZX100 is not specific
for a certain pathway, but instead affects CTGF expression
induced by the activation of several pathways, presumably
because its mechanism of action is downstream and related
to the cytoskeleton.
One of the fundamental problems associated with protein-
based therapeutics is that large molecules such as proteins
and peptides do not cross cell membranes. By using a PTD as
a ‘‘carrier’’, the attached active peptide can be transported
across cell membranes (Schwarze et al., 1999; Flynn et al.,
2003; Snyder and Dowdy, 2004). The PTD used in this study
is an optimized version of TAT (Ho et al., 2001). We observed
that without the PTD, the free HSP20 phosphopeptide had no
effect on TGF-b1-stimulated expression of CTGF and
collagen, demonstrating that the PTD is necessary for intra-
cellular delivery of this active moiety of HSP20 (Figure 1).
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Figure 5. Effect of AZX100 treatment on SMAD3 phosphorylation. Human
keloid fibroblasts were treated as previously indicated. (a) Representative
Western blots of SMAD3, phospho-SMAD3, and b-actin. SMAD3 and
phospho-SMAD3 levels were quantified relative to b-actin expression to
correct for loading differences and normalized to untreated (U) levels. Data
are shown in (b) and are expressed as mean±standard deviation of the ratio
phosphorylated SMAD3/SMAD3 from three experiments. *Po0.05 compared
to the TGF-b1 stimulation.
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Consistent with our in vitro observations regarding the
molecular mechanisms of AZX100, in vivo data demonstrate
a significant impact on collagen fiber orientation, density,
and maturity (Figure 6). This improvement from a single
injection in a rodent model of dermal scarring is comparable
to another molecule currently under development to improve
clinical scar appearance, TGF-b3 (Shah et al., 1995).
Although TGF-b3 has been shown to have in vivo
efficacy in dermal scarring with multiple injections in a
rodent model, the molecular mechanism(s) of action are not
clearly known. TGF-b3 is believed to promote epidermal
homeostasis by preventing keratinocyte apoptosis in culture
and reducing phorbol acetate-induced c-Jun N-terminal
kinase activity (Lee et al., 1999). In addition, TGF-b3 has
been shown to promote palatal shelf adhesion by inducing
chondroitin sulfate proteoglycan expression in mice (Gato
et al., 2002). Clinical trials using recombinant TGF-b3
(Justiva) in various dermal scarring indications have shown
a nominal but significant improvement in scar appearance
(see Renovo Annual Report, http://www.renovo.com/
documents.asp?c_id=52), although the underlying molecular
mechanisms are not clear.
21147
Time (days)
21147
Time (days)
21147
Time (days)
0
2
4
6
8
10
12
To
ta
l c
ol
la
ge
n 
sc
or
e
21147
Time (days)
N.a.N.
0
1
2
3
4
Co
lla
ge
n 
m
at
ur
ity
 s
co
re
*
*
*
N.a.N.0
0
1
2
3
4
Co
lla
ge
n 
or
ie
nt
at
io
n 
sc
or
e
0
1
2
3
4
Co
lla
ge
n 
de
ns
ity
 s
co
re AZX100
Control
Figure 6. AZX100 improved the collagen organization in an in vivo model. (a–f) A linear 2-cm incision was made on the upper back of Siberian hamsters
and injected with 0.1ml of either saline vehicle (control, a–c) or AZX100 (1mM, d–f). Histology slides of samples taken after 7 (a, d), 14 (b, e), or 21 days
(c, f) of healing were stained with trichrome to show collagen fiber organization. (g) Collagen fiber orientation, density, and maturity, as well as the total collagen
scores are shown for 7, 14, and 21 days (n¼ 7–8 per group). *Po0.05 for between-group differences at each time point. Bar¼100 mm.
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Although many different pharmacologic agents have been
studied to improve adult scarring, several of them have failed
to show clinical efficacy despite in vitro and in vivo
preclinical efficacy. For example, IFN-g has been shown to
decrease collagen synthesis in a wide variety of cells,
including human dermal fibroblasts, human chondrocytes,
and rat myofibroblasts (Lee et al., 1999; Phan et al.,
2002; Ragoowansi et al., 2003; Amadeu et al., 2004; Liu
et al., 2004; Wong, 2005; Al-Attar et al., 2006; Davison et al.,
2006; Uysal, 2006). These results were confirmed using
murine models of fibrosis (Sun et al., 1993; Katzung, 1996),
but mixed results were obtained in the clinic (Berman and
Flores, 1998; Davison et al., 2006).
To the best of our knowledge, therapeutic modalities like
AZX100, in which a relevant phosphoprotein motif is directly
delivered inside the cell and modulates downstream events
that regulate scar formation, are previously unreported.
Exploiting posttranslational (for example, phosphorylated)
targets in this pathway may lead to finer, more specific
control of collagen deposition than other pharmacologic
agents that act through receptor-based modulation of signal-
ing cascades, which typically amplify multiple enzymatic
activities. The AZX100 molecule bypasses upstream events,
thus potentially offering a treatment for abnormal wound-
healing processes that respond to multiple upstream events.
Taken together, these findings suggest that AZX100 may
present a molecularly targeted, proteomic therapy for
improving dermal scarring.
MATERIALS AND METHODS
Peptide synthesis
The peptides used in this study were AZX100 (YARAAARQARA-
WLRRAS*APLPGLK; S* denotes phosphoserine), the PTD (YAR-
AAARQARA), and the free HSP20 phosphopeptide (WLRRA-
S*APLPGLK, without a transduction domain). Peptides were
synthesized by UCB-Bioproducts-Lonza (Cambridge, MA) or at
Arizona State University using an automated peptide synthesizer
(Apex 396; Advanced ChemTech, Louisville, KY), and were purified
by fast protein liquid chromatography (Akta Explorer; Amersham
Pharmacia Biotech, Piscataway, NJ).
Cell culture
Human keloid fibroblasts were isolated from three different patients
in accordance with the Declaration of Helsinki Principles 1975 and
with protocols approved by the Human Subjects Institutional Review
Board at Stanford University and maintained as previously described
(Phan et al., 2005; Xia et al., 2006). Cells were grown at 37 1C and
10% CO2 atmosphere in DMEM (Mediatech, Harndon, VA)
containing 10% fetal bovine serum (Gibco, Carlsbad, CA) and
additional penicillin and streptomycin (1%) in 10 cm2 dishes. When
the cells reached 70% confluence, they were growth-arrested by
reducing the concentration of fetal bovine serum in the media to
0.5% for 48 hours before the experiment.
Cell treatment
Cells were either nonstimulated (control) or stimulated for 24 hours
with TGF-b1 (R&D systems, Minneapolis, MN; 0.6–5 ngml1) in the
presence or absence of AZX100 (5–50 mM). In separate experiments,
the cells were stimulated with other profibrotic mediators: thrombin
(Sigma, St Louis, MO; 50–150 nM), ET (Sigma; 10–100 nM), or LPA
(Sigma; 10–50 mM).
Western blot analysis
At the end of the experiments, adherent cells were rinsed with
phosphate-buffered saline, and lysed using UDC buffer (8 M urea,
10mM dithiothreitol, 4% 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate). Equal amounts of protein (20 mg per lane) were
loaded on 15, 10, or 4–20% SDS–PAGE gels; proteins were
electrophoretically separated, and then transferred to Immobilon
membranes (Millipore, Billerica, MA). Membranes were probed
overnight at 4 1C with the following primary antibodies: rabbit anti-
CTGF (Torrey Pines Biolabs, Houston, TX), rabbit anti-collagen
(Cortex Biochem, San Leandro, CA), mouse anti-cofilin (BD
Biosciences, San Jose, CA), rabbit anti-phosphorylated cofilin (a gift
from Dr James Bamburg), mouse anti-a-SMA (Sigma), mouse anti-
GAPDH (Chemicon, Temecula, CA), and rabbit anti-b-actin (Sigma).
After washing, the membranes were incubated with appropriate
secondary antibodies (Li-Cor) for 1 hour at room temperature. The
protein–antibody complexes were visualized using the Odyssey
direct infrared fluorescence imaging system (Li-Cor).
Cytoskeleton staining
Human keloid fibroblasts were grown on glass coverslips in six-well
dishes at a density of 2.0 105 cells per well. On the following day,
cells were treated as indicated above, fixed with 4% paraformalde-
hyde for 1 hour, permeabilized with 0.1% Triton X for 15minutes,
and incubated for 1 hour with Alexa 350 phalloidin (Invitrogen,
Eugene, OR) to stain the actin cytoskeleton. Images were obtained
using a fluorescence microscope (Axiovert 200; AxioVision software,
Carl Zeiss, Thornwood, NY).
Hamster model of dermal scarring
All procedures were carried out with approval from the Arizona State
University Institutional Animal Care and Use Committee. Siberian
hamsters (4–6 months) were obtained from Kathleen Matt. The animals
were anesthetized using ketamine–xylazine–acepromazine (21, 2.4, and
0.03mgkg1, i.p.). The area on the upper back was shaved, scrubbed
with chlorhexidine, and a single linear incision (2cm in length)
extending through the dermis, epidermis, and into the subcutaneous fat
was made on the upper back. The incision was then closed with
interrupted 4–0 nylon sutures. AZX100 (100ml of 1mM) or saline was
injected under the skin on each side of the incision immediately after
closure (n¼ 7–8 animals per group). Sutures were removed after 1
week, and animals were killed at 7, 14, and 21 days after surgery by
inhalation of carbon dioxide. These time points are consistent with
previous studies by Shah et al. (1995). The healing wounds and
adjacent skin (as a control) were excised, histologically processed, and
stained by Masson’s trichrome method to reveal collagen fibers. Each
specimen was analyzed by light microscopy under multiple magnifica-
tions by a dermal pathologist, who blindly scored (in duplicate) the
specimens for dermal collagen fiber orientation, density, and maturity
using an established scoring scale (Beausang et al., 1998).
Statistical analysis
All protein expression data are presented as means±SD. The
Western blot bands were quantified by densitometry, and protein
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expression was normalized by the loading control (glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) or b-actin) expression. One-
way analysis of variance followed by Tukey’s test was used to
compare experimental groups, with a significance level of Po0.05.
Histology data were analyzed as the average of the duplicate scores.
Group means and standard error values were calculated for the
collagen fiber orientation, density, and maturity, as well as the total
collagen score (sum of all three categories). Statistical analysis was
performed with SigmaStat software (version 3.11.0; Systat Software
Inc., San Jose, CA). Between-group differences at each time point
were evaluated by the Mann–Whitney rank-sum test. Exact, two-
sided P-values o0.05 were considered significant.
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